ArteraAI test expands to inform decisions for active surveillance in prostate cancer

The ArteraAI test has been updated to include personalized insights on a patients’ relative risk of their prostate cancer showing more aggressive features, helping to inform the decision between active surveillance and active treatment in patients with lower risk prostate cancer, Artera, the developer of the test, announced in a news release.¹

Earlier this year, the ArteraAI Prostate test was included in the NCCN guidelines for localized prostate cancer.

ArteraAI is a multimodal artificial intelligence (MMAI) biomarker test that uses patients’ digital biopsy images and clinical data to help predict which patients may benefit from a particular therapy. The prognostic test has now been validated in patients who have undergone active surveillance, radiation therapy, or had a radical prostatectomy.

“With this expansion, we are proud to reinforce the reliability and robustness of the ArteraAI Prostate Test for a broader community of clinicians and patients," said Andre Esteva, CEO of Artera, in the news release.¹ "Our mission is to empower all those delivering cancer care, from the laboratory to clinical practice, to realize the promise of precision medicine.”

The update to the test comes on the heels of a funding announcement from the company in February.² Artera announced that they had received an additional $20 million in capital from several large investment funds to support international expansion of their prostate cancer test. The company also recently announced a collaboration with PathNet, a digital pathology lab, to further extend the distribution of the ArteraAI test across 27 states in the US.

Additionally, earlier this year, the ArteraAI Prostate test was included in the National Comprehensive Cancer Center (NCCN) guidelines for localized prostate cancer.³ In the NCCN guidelines, the biomarker test is classified as having a Level IB evidence rating per Simon Criteria. The test is also included as a Category 2A recommendation, signifying a uniform NCCN consensus on the usefulness of the tool as an option in prostate cancer.

Artera concluded in the news release on the test expansion, “Artera plans to continue further validation of its MMAI platform and inclusion of new insights to the test report in order to provide greater confidence in treatment decision-making to those facing cancer.”¹

References

1. Artera announces expansion of the ArteraAI Prostate Test to inform active surveillance decisions for lower risk prostate cancer patients. News release. Artera. Published online and accessed August 6, 2024. https://www.businesswire.com/news/home/20240806340589/en/Artera-Announces-Expansion-of-the-ArteraAI-Prostate-Test-to-Inform-Active-Surveillance-Decisions-for-Lower-Risk-Prostate-Cancer-Patients

2. ArteraAI secures $20 million in funding to further personalize cancer therapy with multimodal AI. News release. Artera. February 1, 2024. Accessed August 6, 2024. https://www.businesswire.com/news/home/20240201133920/en/ArteraAI-Secures-20-Million-in-Funding-to-Further-Personalize-Cancer-Therapy-With-Multimodal-AI

3. ArteraAI announced as the first-and-only predictive test for therapy personalization in the 2024 NCCN Guidelines for prostate cancer. News release. Artera. March 4, 2024. Accessed August 6, 2024. https://www.businesswire.com/news/home/20240304893588/en/ArteraAI-Announced-as-the-First-and-Only-Predictive-Test-for-Therapy-Personalization-in-the-2024-NCCN-Guidelines%C2%AE-for-Prostate-Cancer